Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairmentLong-term...
Cedric Ogorman Tim Mccarthy Securities Exchange Clinical Research Program Relmada Therapeutics Inc Prnewswire Relmada Therapeutics Inc
Source: marketscreener.com